Advertisement

Once a Week Transdermal Estrogen—Quality of Life Improvement in Long-Term Replacement Therapy: Newest Findings

  • Patrick Marquis
  • Ch. Lademacher
  • H. Rozenbaum
Part of the Medical Science Symposia Series book series (MSSS, volume 13)

Abstract

Menopause is characterized by the cessation of ovarian function, leading to permanent amenorrhoea and the absence of circulating estrogen in the systemic circulation [1]. Menopause has been viewed as a hormone deficiency or as a natural aging process in women. Nevertheless, it has been acknowledged to result in significant morbidity and mortality and associated reduction in quality of life [2]. All women who live long enough will experience menopause. The average age of menopause remains stable at around 50 years of age, and with increased life expectancy in the industrialized world, women may expect to live one third of their lifetime after menopause [3].

Keywords

Hormone Replacement Therapy Vasomotor Symptom Sickness Impact Profile Climacteric Symptom Menstrual Symptom 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Burger HG. The endocrinology of the menopause. Maturitas 1996;23:129–36.PubMedCrossRefGoogle Scholar
  2. 2.
    Oldenhave A, Jaszmann LJB, Haspels AA, Everaerd TAM. Impact of the climacteric on well-being. Am J Obstet Gynecol 1993;168(3):772–80.PubMedGoogle Scholar
  3. 3.
    Hill K. The demography of menopause. Maturitas 1996;23:113–27.PubMedCrossRefGoogle Scholar
  4. 4.
    Dennerstein L. Well-being, symptoms, and the menopausal transition. Maturitas 1996;23:147–57.PubMedCrossRefGoogle Scholar
  5. 5.
    Lomax P, Schönbaum S. Postmenopausal hot flushed and their management. Pharmac Therap 1993;57:347–58.CrossRefGoogle Scholar
  6. 6.
    Wiklund I, et al. Quality of life of postmenopausal women on a regimen of transdermal estradiol therapy. Am J Obstet Gynecol 1993;168:824–30.PubMedGoogle Scholar
  7. 7.
    Nathorst-Böös J, et al. Is sexual life influenced by transdermal estrogen therapy? Acta Obstet Gynecol Scand 1993;72:656–60.PubMedGoogle Scholar
  8. 8.
    Limouzin-Lamothe MA, et al. Quality of life after the menopause: Influence of hormonal replacement therapy. Am J Obstet Gynecol 1994;170(2):618–24.PubMedGoogle Scholar
  9. 9.
    Hunter M. The Women’s Health Questionnaire: A measure of mid-aged women’s perceptions of their emotional and physical health. Psychology and Health 1992;7:45–55.Google Scholar
  10. 10.
    Bergner M, Bobbitt RA, Pollard WE, Martin DP, Gilson BS. The Sickness Impact Profile: Validation of a health status measure. Med Care 1976:14(1):57–67.PubMedCrossRefGoogle Scholar
  11. 11.
    Bergner M, The Sickness Impact Profile: A brief summary of its purpose, uses, and administration. Baltimore, Maryland: The Johns Hopkins University, 1977.Google Scholar
  12. 12.
    DeBruin AF, De Witte LP, Stevens F, Diederiks JPM. Sickness Impact Profile: The state of the art of a generic functional status measure. Soc Sci Med 1992;35(8):1003–14.CrossRefGoogle Scholar

Copyright information

© Kluwer Academic Publishers and Fondazione Giovanni Lorenzini 1999

Authors and Affiliations

  • Patrick Marquis
  • Ch. Lademacher
  • H. Rozenbaum

There are no affiliations available

Personalised recommendations